Regulatory authorities in China have cracked down on Sun Pharma’s rivastigmine-based Alzheimer’s disease treatment, halting ...

After posting 16.2% revenue growth in the last financial year, Servier President Olivier Laureau said the company has moved ...

The drugmaker has recruited Will Forte, who appeared on “SNL” for nearly a decade in the aughts, perhaps most memorably as ...

In an agreement that seemingly bodes well for the flow of pharmaceuticals between the two regions, the EU and India on Monday agreed to a sweeping free trade agreement that the European bloc has ...

Swiss CDMO Sigfried has been on a growth jag over the last decade. | Siegfried has signed agreements to acquire the controlled drug substance businesses of the Noramco Group and Extractas Bioscience.

But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good standing with physicians.

Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it's planning to wind down cell ...

Arcutis Biotherapeutics and Kowa Pharmaceuticals are cutting ties on their U.S. marketing partnership around Arcutis’ Zoryve ...

With the FDA tightening its guidance around the production of nonbacterial beta-lactam drugs, Swedish CDMO Recipharm is ...

With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug conjugates. | With Enhertu and Datroway, Daiichi Sankyo has made itself a top-tier player in antibody-drug ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. | GLP-1 ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...